High expression of heat shock proteins and heat shock factor-1 distinguishes an aggressive subset of clear cell renal cell carcinoma

Multifaceted roles of HSF1 in cancer

(2015) Sufang Jiang et al.   TUMOR BIOLOGY

Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia

(2015) Siddhartha Ganguly et al.   Oncotarget

The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters

(2013) Brett Delahunt et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Prognostic significance of heat shock proteins in urothelial carcinoma of the urinary bladder

(2012) Hui-Jung Yu et al.   HISTOPATHOLOGY

Heat Shock Transcription Factor Hsf1 Is Involved in Tumor Progression via Regulation of Hypoxia-Inducible Factor 1 and RNA-Binding Protein HuR

(2012) V. L. Gabai et al.   MOLECULAR AND CELLULAR BIOLOGY

Protein Expression Profiling in the Spectrum of Renal Cell Carcinomas

(2012) Vladimir A Valera et al.   Journal of Cancer

Molecular Mechanism of Protein Folding in the Cell

(2011) James E. Rothman et al.   CELL

Degradation of HIF-1alpha under Hypoxia Combined with Induction of Hsp90 Polyubiquitination in Cancer Cells by Hypericin: a Unique Cancer Therapy

(2011) Tilda Barliya et al.   PLoS One

The heat shock factor family and adaptation to proteotoxic stress

(2010) Mitsuaki Fujimoto et al.   FEBS Journal

Dual Role of Heat Shock Proteins as Regulators of Apoptosis and Innate Immunity

(2010) Anne-Laure Joly et al.   Journal of Innate Immunity

Expression of potential molecular markers in renal cell carcinoma: impact on clinicopathological outcomes in patients undergoing radical nephrectomy

(2009) Iori Sakai et al.   BJU INTERNATIONAL

Prognostic Models With Competing Risks

(2009) Marcel Wolbers et al.   EPIDEMIOLOGY

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings

(2008) E Jonasch et al.   BRITISH JOURNAL OF CANCER

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

(2008) Christopher Wood et al.   LANCET